Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.49 |
| ▸ | CDK4 | P11802 | 14/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.41 |
| ▸ | CDK1 | P06493 | 10/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.41 |
| ▸ | CCND3 | P30281 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393120 | 0.87 | BTK (0.38) | BTKCDK4CDK1CDK2CDK6 | |
| SCHEMBL1392855 | 0.81 | BTK (0.50) | BTKCDK4CCNE1CDK1CCNB1 | |
| SCHEMBL10255910 | 0.78 | MAPT (0.47) | BTKCDK4CDK2CDK6JAK2 | |
| SCHEMBL1393892 | 0.78 | CDK4 (0.40) | CDK4CDK1CCND3CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL1394003 | 0.77 | CDK4 (0.40) | CDK4CDK1CCND3CCNA2CDK2 | |
| SCHEMBL10256111 | 0.74 | BTK (0.47) | BTK | |
| SCHEMBL1392842 | 0.72 | BTK (0.49) | BTKCDK4CCNA2CDK2CDK6 | |
| SCHEMBL14913184 | 0.71 | HTR3A (0.43) | BTK | |
| SCHEMBL31158079 | 0.71 | HTR3A (0.43) | BTK | |
| SCHEMBL1393041 | 0.71 | BTK (0.40) | BTKCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818724-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-107253963-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-04-14 | — | — | CN | disclosed |
| CN-110818724-A | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9505785-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2566869-B1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-8618107-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2566869-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | Gilead Connecticut, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | BTK 2/4885CDK4 146/4885CCNE1 1181/4885 |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | BTK 2/4885CDK4 146/4885CCNE1 1181/4885 |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | BTK 2/4885CDK4 146/4885CCNE1 1181/4885 |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | BTK 2/4885CDK4 146/4885CCNE1 1181/4885 |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | BTK 2/4885CDK4 146/4885CCNE1 1181/4885 |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | BTK 2/4885CDK4 119/4885CCNE1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.